Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorKilpeläinen, Athina
dc.contributor.authorSaubí Roca, Narcís
dc.contributor.authorGuitart, Núria
dc.contributor.authorOlvera, Alex
dc.contributor.authorHanke, Tomáš
dc.contributor.authorBrander, Christian
dc.contributor.authorJoseph Munné, Joan
dc.date.accessioned2020-02-24T10:59:21Z
dc.date.available2020-02-24T10:59:21Z
dc.date.issued2019-08-02
dc.identifier.citationKilpeläinen A, Saubi N, Guitart N, Olvera A, Hanke T, Brander C, et al. Recombinant BCG expressing HTI prime and recombinant ChAdOx1 boost is safe and elicits HIV-1-specific T-cell responses in BALB/c mice. Vaccines. 2019 Aug 2;7(3):78.
dc.identifier.issn2076-393X
dc.identifier.urihttp://hdl.handle.net/11351/4671
dc.descriptionBCG; HIV; Vaccine
dc.description.abstractDespite the availability of anti-retroviral therapy, HIV-1 infection remains a massive burden on healthcare systems. Bacillus Calmette-Guérin (BCG), the only licensed vaccine against tuberculosis, confers protection against meningitis and miliary tuberculosis in infants. Recombinant BCG has been used as a vaccine vehicle to express both HIV-1 and Simian Immunodeficiemcy Virus (SIV) immunogens. In this study, we constructed an integrative E. coli-mycobacterial shuttle plasmid, p2auxo.HTI.int, expressing the HIVACAT T-cell immunogen (HTI). The plasmid was transformed into a lysine auxotrophic Mycobacterium bovis BCG strain (BCGΔLys) to generate the vaccine BCG.HTI2auxo.int. The DNA sequence coding for the HTI immunogen and HTI protein expression were confirmed, and working vaccine stocks were genetically and phenotypically characterized. We demonstrated that the vaccine was stable in vitro for 35 bacterial generations, and that when delivered in combination with chimpanzee adenovirus (ChAd)Ox1.HTI in adult BALB/c mice, it was well tolerated and induced HIV-1-specific T-cell responses. Specifically, priming with BCG.HTI2auxo.int doubled the magnitude of the T-cell response in comparison with ChAdOx1.HTI alone while maintaining its breadth. The use of integrative expression vectors and novel HIV-1 immunogens can aid in improving mycobacterial vaccine stability as well as specific immunogenicity. This vaccine candidate may be a useful tool in the development of an effective vaccine platform for priming protective responses against HIV-1/TB and other prevalent pediatric pathogens.
dc.language.isoeng
dc.publisherMDPI
dc.relation.ispartofseriesVaccines;7(3)
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectMycobacterium tuberculosis
dc.subjectVacunes antivíriques
dc.subjectSida - Vacunació
dc.subject.meshAIDS Vaccines
dc.subject.meshImmunogenicity, Vaccine
dc.subject.meshMycobacterium bovis
dc.titleRecombinant BCG expressing HTI prime and recombinant ChAdOx1 boost is safe and elicits HIV-1-specific T-cell responses in BALB/c mice
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.3390/vaccines7030078
dc.subject.decsvacunas para SIDA
dc.subject.decsinmunogenicidad vacunal
dc.subject.decsMycobacterium bovis
dc.relation.publishversionhttps://www.mdpi.com/2076-393X/7/3/78
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.authoraffiliation[Kilpeläinen A, Saubi N, Joseph J] Catalan Center for HIV Vaccine Research and Development, AIDS Research Unit, Servei de Malalties Infeccioses, Hospital Clínic/Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain. Hospital Universitari Vall d’Hebron, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. [Guitart N] Catalan Center for HIV Vaccine Research and Development, AIDS Research Unit, Servei de Malalties Infeccioses, Hospital Clínic/Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain. [Olvera A] Irsicaixa AIDS Research Institute, Badalona, Spain. Universitat de Vic-Universitat Central de Catalunya (UVic-UCC), Barcelona, Spain. [Hanke T] Nueld Department of Medicine, The Jenner Institute, University of Oxford, Oxford, UK. International Research Center of Medical Sciences (IRCMS), Kumamoto University, Kumamoto, Japan. [Brander C] ] Irsicaixa AIDS Research Institute, Badalona, Spain. Universitat de Vic-Universitat Central de Catalunya (UVic-UCC), Barcelona, Spain. ICREA, Barcelona, Spain. AELIX Therapeutics, Barcelona, Spain
dc.identifier.pmid31382453
dc.identifier.wos000487982000034
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record